Skip to main content
. 2022 Jan 25;9:784024. doi: 10.3389/fped.2021.784024

Figure 5.

Figure 5

Proposed approach to HSCT consolidation after CAR-T for paediatric patients and AYA with BCP-ALL based on treatment- and disease-related risk factors for relapse. *MRD positivity defined at >0.01%. AUC, area under the curve; AYA, adolescent and young adult; BCA, B-cell aplasia; CAR-T, chimeric antigen receptor T-cell therapy; FCM, flow cytometry; HSCT, haematopoietic stem cell transplantation; KMT2A, lysine methyltransferase 2A; MRD, minimal residual disease; NGS, next-generation sequencing; OOS, out of specification; PCR, polymerase chain reaction.